NO832700L - Fremgangsmaate for fremstilling av en pyridylalkylnitratforbindelse. - Google Patents
Fremgangsmaate for fremstilling av en pyridylalkylnitratforbindelse.Info
- Publication number
- NO832700L NO832700L NO832700A NO832700A NO832700L NO 832700 L NO832700 L NO 832700L NO 832700 A NO832700 A NO 832700A NO 832700 A NO832700 A NO 832700A NO 832700 L NO832700 L NO 832700L
- Authority
- NO
- Norway
- Prior art keywords
- nitroxymethyl
- lower alkyl
- hydrogen
- produced
- halogen
- Prior art date
Links
- -1 NITRATE COMPOUND Chemical class 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 19
- 229910002651 NO3 Inorganic materials 0.000 title claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- 150000002367 halogens Chemical class 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 5
- KLKMRHCMLLGCSZ-UHFFFAOYSA-N (6-chloropyridin-2-yl)methyl nitrate Chemical compound [O-][N+](=O)OCC1=CC=CC(Cl)=N1 KLKMRHCMLLGCSZ-UHFFFAOYSA-N 0.000 claims description 3
- HKLBNRHIHKYZTB-UHFFFAOYSA-N 3-pyridin-4-ylpropyl nitrate Chemical compound [O-][N+](=O)OCCCC1=CC=NC=C1 HKLBNRHIHKYZTB-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- QEBGRZOEFXKNIZ-UHFFFAOYSA-N [4-chloro-6-(nitrooxymethyl)pyridin-2-yl]methyl nitrate Chemical compound [O-][N+](=O)OCC1=CC(Cl)=CC(CO[N+]([O-])=O)=N1 QEBGRZOEFXKNIZ-UHFFFAOYSA-N 0.000 claims description 3
- IBYVZIVEQGSCBX-UHFFFAOYSA-N [6-(nitrooxymethyl)pyridin-2-yl]methyl nitrate Chemical compound [O-][N+](=O)OCC1=CC=CC(CO[N+]([O-])=O)=N1 IBYVZIVEQGSCBX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000000802 nitrating effect Effects 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- GQLQYSTXJVGYFH-UHFFFAOYSA-N (3-nitrooxy-2-pyridin-2-ylpropyl) nitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)C1=CC=CC=N1 GQLQYSTXJVGYFH-UHFFFAOYSA-N 0.000 claims 1
- PCCCBXSNMNEXFD-UHFFFAOYSA-N (6-methylpyridin-2-yl)methyl nitrate Chemical compound CC1=CC=CC(CO[N+]([O-])=O)=N1 PCCCBXSNMNEXFD-UHFFFAOYSA-N 0.000 claims 1
- SLPBIRAFWRSHME-UHFFFAOYSA-N 2-pyridin-2-ylethyl nitrate Chemical compound [O-][N+](=O)OCCC1=CC=CC=N1 SLPBIRAFWRSHME-UHFFFAOYSA-N 0.000 claims 1
- AWWPAOSCTMXHNS-UHFFFAOYSA-N pyridin-2-ylmethyl nitrate Chemical compound [O-][N+](=O)OCC1=CC=CC=N1 AWWPAOSCTMXHNS-UHFFFAOYSA-N 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UOMMGMRPOFXGTJ-UHFFFAOYSA-N (3-nitrooxy-2-pyridin-2-ylpropyl) nitrate;hydrochloride Chemical compound Cl.[O-][N+](=O)OCC(CO[N+]([O-])=O)C1=CC=CC=N1 UOMMGMRPOFXGTJ-UHFFFAOYSA-N 0.000 description 1
- OETZAKJXBYDYBR-UHFFFAOYSA-N (6-methylpyridin-2-yl)methyl nitrate;hydrochloride Chemical compound Cl.CC1=CC=CC(CO[N+]([O-])=O)=N1 OETZAKJXBYDYBR-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- WWFMINHWJYHXHF-UHFFFAOYSA-N [6-(hydroxymethyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=CC(CO)=N1 WWFMINHWJYHXHF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- KIINPFQQESVOCG-UHFFFAOYSA-N nitric acid;2-pyridin-2-ylethyl nitrate Chemical compound O[N+]([O-])=O.[O-][N+](=O)OCCC1=CC=CC=N1 KIINPFQQESVOCG-UHFFFAOYSA-N 0.000 description 1
- ZXQRXDAJXVXLMA-UHFFFAOYSA-N nitric acid;pyridin-2-ylmethanol Chemical compound O[N+]([O-])=O.OCC1=CC=CC=N1 ZXQRXDAJXVXLMA-UHFFFAOYSA-N 0.000 description 1
- RCBXZFKSOOZDKI-UHFFFAOYSA-N nitric acid;pyridin-2-ylmethyl nitrate Chemical compound O[N+]([O-])=O.[O-][N+](=O)OCC1=CC=CC=N1 RCBXZFKSOOZDKI-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- AKAPLDZCZUFYKJ-UHFFFAOYSA-N pyridin-3-ylmethyl nitrate Chemical compound [O-][N+](=O)OCC1=CC=CN=C1 AKAPLDZCZUFYKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Foreliggende oppfinnelse angår en fremgangsmåte for fremstilling av pyridylalkylnitratforbindelser og salter derav.
Mer spesielt angår oppfinnelsen en fremgangsmåte for fremstilling av hittil ukjente pyridylalkylnitratforbindelser og farmasøytisk godtagbare salter derav som har vasodilaterende virkning. Oppfinnelsen gjør det mulig å fremstille et farmasøytisk preparat som omfatter disse forbindelser for terapeutisk behandling av kardiovaskulære forstyrrelser hos mennesker.
Med hensyn til tidligere kjent teknikk innen dette område,
er f.eks. følgende pyridylalkylnitratforbindelse kjent.
Et formål med foreliggende oppfinnelse er å tilveiebringe hittil ukjente og nyttige pyridylalkylnitratforbindelser og farmasøytisk godtagbare salter derav som har en sterkere virkning sammenlignet med kjente forbindelser, f.eks. som vist ovenfor.
Ved oppfinnelsen tilveiebringes en fremgangsmåte for fremstilling av nevnte pyridylalkylnitratforbindelse og salter derav.
Det kan fremstilles et nyttig farmasøytisk preparat som som aktiv bestanddel, omfatter nevnte pyridylalkylnitratforbindelser eller farmasøytisk godtagbare salter derav, og som er nyttig som vasodilaterende middel.
Forbindelsene kan anvendes ved en terapeutisk metode
for behandling av kardiovaskulære forstyrrelser så som coronar-insufficiens, angina pectoris eller myocardialt infarkt.
Pyridylalkylnitratforbindelser fremstilt ved fremgangsmåten ifølge oppfinnelsen kan representeres ved følgende generelle formel I hvor R er hydrogen, lavere alkyl, halogen eller nitroksy-lavere alkyl, én av R 2 og R 3 er mono- eller di-nitroksy-lavere
2 3
alkyl og den annen av R og R er hydrogen eller halogen.
Ved fremgangsmåten ifølge oppfinnelsen kan sluttproduktet med den generelle formel I fremstilles som vist i det følgende reaksjonsskjerna.
12 3
hvor R , R og R hver er som ovenfor angitt,
R^ er hydrogen, lavere alkyl, halogen eller hydroksy-lavere alkyl,
2 3
én av R og R er mono- eller di-hydroksy-lavere alkyl og den
2 3
annen av R& og er hydrogen eller halogen.
Egnede farmasøytisk godtagbare salter av forbindelsene med den generelle formel I er vanlige, ugiftige salter og omfatter et syreaddisjonssalt så som et organisk syresalt (f.eks. acetatet, trifluoracetatet, maleatet, tartratet, metansulfonatet, benzen-sulfonatet, formiatet, toluensulfonatet etc), et uorganisk syresalt (f.eks. hydrokloridet, hydrobromidet, hydrojodidet, sulfatet, nitratet, fosfatet etc.) eller et salt med en aminosyre (f.eks. arginin, asparaginsyre, glutaminsyre etc.) eller lignende.
I det følgende angis detaljert hensiktsmessige eksempler og illustrasjoner på de forskjellige definisjoner som inngår i'beskrivelsen.
Betegnelsen "lavere" angir, hvis ikke annet er angitt,
fra 1 til 6 karbonatomer.
Egnede "lavere alkyl"-grupper og "lavere alkyl"-deler
i betegnelsene "nitroksy-lavere alkyl", "mono- eller di-nitroksy-lavere alkyl", "hydroksy-lavere alkyl" og "mono- eller di-hydroksy-lavere alkyl" er dé'som har fra 1 til 6 karbonatomer og kan omfatte metyl, etyl, propyl, isopropyl, butyl, isobutyl, tert.butyl, pentyl, tert.pentyl, heksyl og lignende, fortrinnsvis de som har fra 1 til 4 karbonatomer.
Egnet halogen kan omfatte klor, brom, fluor og jod.
Egnede reaktive derivater ved hydroksygruppen(e) i "hydroksy-lavere alkyl" og "mono- eller di-hydroksy-lavere alkyl" kan omfatte en syrerest så som halogen som nevnt ovenfor eller lignende.
Fremgangsmåten for fremstilling av pyridylalkylnitrat-forbindelsene med den generelle formel I er forklart detaljert i det følgende.
En forbindelse med den generelle formel I eller et salt
derav kan fremstilles ved å omsette en forbindelse med den generelle formel II eller salter derav eller reaktive derivater derav ved hydroksygruppen(e) på hydroksy-lavere alkyl-gruppen(e) med et nitreringsmiddel.
Med hensyn til egnede salter av forbindelsene med den generelle formel II henvises til de salter som er beskrevet for forbindelsene med den generelle formel I.
Egnede nitreringsmidler for anvendelse ved fremgangsmåten
kan omfatte salpetersyre, en kombinasjon av eddiksyreanhydrid og salpetersyre eller en kombinasjon av konsentrert svovelsyre og salpetersyre, eller lignende.
Reaksjonstemperaturen er ikke kritisk, og omsetningen
utføres vanligvis under avkjøling eller ved omgivelsestemperatur.
Omsetningen utføres vanligvis uten oppløsningsmiddel eller
i et oppløsningsmiddel så som eddiksyre eller et annet konvensjonelt oppløsningsmiddel som ikke påvirker reaksjonen ugustig.
Den således oppnådde forbindelse med den generelle formel I kan på konvensjonell måte omdannes til et farmasøytisk godtagbart salt derav.
For terapeutiske formål administreres pyridylalkylnitratforbindelsen med den generelle formel I i daglige doser på fra 0/01 til 50 mg, fortrinnsvis fra 0,1 til 10 mg.
Farmasøytiske preparater omfatter som aktiv bestanddel, pyridylalkylnitratforbindelsen med den generelle formel I eller et farmasøytisk godtagbart salt derav i en mengde på fra ca.
0,01 mg til ca. 10 mg, fortrinnsvis fra ca. 0,01 mg til ca. 5 mg pr. doseenhet for oral og parenteral anvendelse.
Det vil være klart for en fagmann at mengden av aktiv bestanddel i enhetsdoseformen kan bestemmes ved å ta i betraktning virkningen av den aktive bestanddel såvel som pasientens størrelse. Den aktive bestanddel kan vanligvis tilberedes i fast form så som tabletter, granuler, pulvere, kapsler, pastiller, piller eller suppositorier, eller i form av en suspensjon eller oppløsning, så som en sirup, injeksjonspreparat, emulsjon, limonade og lignende.
Et farmasøytisk bæremiddel eller fortynningsmiddel omfatter faste eller flytende ikke-toksiske, farmasøytisk godtagbare stoffer. Eksempler på faste eller flytende bæremidler eller fortynningsmidler er laktose, magnesiumstearat, terra alba, sakkarose, maisstivelse, talk, stearinsyre, gelatin, agar, pektin, akasiegummi, jordnøttolje, olivenolje eller sesamolje, kakaosmør, etylenglykol eller andre vanlige stoffer. Likeledes kan bære-midlet eller fortynningsmidlet omfatte et materiale som forårsaker forsinket avgivelse, så som glycerylmonostearat, glyceryldistearat en voksart og lignende.
For å demonstrere den nyttige virkning av forbindelsene med den generelle formel I er det i det følgende vist farmakologiske testresultater for noen representative forbindelser.
Virkning på isolert coronararterie
Testmetode:
Den store og den lille coronararterie, med utvendig diameter på henholdsvis 2,0 og 0,5 mm, ble fjernet fra pentobarbital-bedøvede hunder. Spiralstrimler med en lengde på ca. 15 og 5 mm ble skåret ut fra henholdsvis den store og den lille arterie og hengt opp i et organbad inneholdende Tyrodes oppløsning ved 37°C som ble gjennomstrømmet med en gassblanding bestående av
95% oksygen og 5% kulldioksyd. Tonus av strimlene ble skrevet ut på en polygraf via en kraftforskyvningstransduser. Efter at den initiale hvilespenning var blitt justert til 1,0 g for den store arterie og 100 mg for den lille arterie ble det til organbadet
satt 35 mM kaliumklorid for å øke tonus av strimlene fra den store arterie til 1,4-1,6 g og av strimlene fra den lille arterie til 120-140 mg. De kumulative konsentrasjoner av prøve-forbindelsene ble derefter tilsatt, og til slutt ble det tilsatt 10 -4M papaverin for å bestemme den maksimale relaksasjon. EDj-Q-verdier ble beregnet ved interpolering fra de gjennom-snittlige kumulative dose-virkningskurver (virkning av 10<4>M papaverin = 100%).
Prøveforbindelser:
Forbindelse A: 3-nitroksymetylpyridin (referanseforbindelse) Forbindelse B: 2,6-bis(nitroksymetyl)pyridin
Forbindelse C: 4-(3-nitroksypropyl)pyridin
Forbindelse D: 2-nitroksymetyl-6-klorpyridin
Forbindelse E: 2,6-bis(nitroksymetyl)-4-klorpyridin.
Testresultater:
Verdiene er angitt i den nedenstående tabell.
Som det sees av testresultatene i tabellen, særlig av S/L-verdiene, er det klart at forbindelsene fremstilt ved fremgangsmåten ifølge oppfinnelsen erkarakterisert vedat de har en kraftig og selektiv dilaterende virkning på store coronararterier sammenlignet med små coronararterier, hvilket betyr at forbindelsene fremstilt ved fremgangsmåten ifølge oppfinnelsen er nyttige for behandling av cardiovaskulære forstyrrelser.
Tabell
ED50g/ml
Forbindelse Stor ( L) Liten ( S) S/ L
A 8,0 x 10~<8>1,9 x IO"<6>23,8 B 4,0 x IO"<9>2,25 x 10~<7>56,3 C 1,25 x 10~<8>>1,0 x 10~<5>>800
D 6,7 x 10~<9>6,2 x IO<-6>925
E 2,75 xio"<9>2,30 x 10~<7>83,6
Oppfinnelsen illustreres ved følgende eksempler.
Eksempel 1
Rykende salpetersyre (4,1 ml) ble satt dråpevis til eddiksyreanhydrid (13,5 ml) under omrøring ved 5-lO°C. Efter omrøring av blandingen ved 5°C i 30 minutter ble 2-hydroksymetyl-pyridin-nitrat (3,3 g) tilsatt i flere porsjoner. Den resulterende blanding ble omrørt i 3 timer ved 0-5°C. En blanding av benzen (15 ml) og n-heksan (30 ml) ble tilsatt. Blandingen dannet to faser. Den øvre fase ble fraskilt og kastet, mens den gjenværende nedre fase igjen ble behandlet med en blanding av benzen (10 ml) og n-heksan (10 ml). Efter adskillelse av fasene ble den nedre fase igjen fraskilt, blandet med benzen
(10 ml) og gjort homogen ved hjelp av isopropylalkohol (10 ml). Den resulterende blanding fikk stå natten over i et kjøleskap for å få dannet krystaller. Krystallene ble oppsamlet ved filtrering og vasket med dietyleter, hvilket ga hvite krystaller av 2-nitroksymetylpyridinnitrat (2,4 g), sm.p. 75-77°C. IR-spektrum (nujol) : ^ ma] liS = 2450, 2050, 1645, 1430, 1280 og
840 cm<-1>.
NMR-spektrum (dimetylsulfoksyd : 6 (ppm) = 5,85 (2H, s), 7,65-8,1 (2H, m), 8,1-8,5 (1H, m), 9,85 (1H, dd, J=5,5 og 1Hz), 14,95 (1H, s).
Analyse:
Beregnet for CgHgN^ ,HN03: C 33,19, H 3,25, N 19,35
Funnet: C 32,86, H 3,17, N 19,31
Eksempel 2
Rykende salpetersyre (5 ml) ble dråpevis satt til eddiksyreanhydrid (9,5 ml) under omrøring ved 5-10°C. Til dette ble
satt 2,6-bis(hydroksymetyl)pyridin (6,95 g). Den resulterende blanding ble omrørt i 20 minutter ved 5-10°C og i ytterligere 1,5 time ved 20°C og ble derefter hellet i en blanding av etyl-acetat (40 ml) og isvann (60 ml). Den resulterende blanding ble nøytralisert med.vandig kaliumkarbonatoppløsning. Etylacetat-fasen ble fraskilt, vasket med vann, tørret over vannfritt magnesiumsulfat og konsentrert under redusert trykk. Det oppnådde residuum ble underkastet kolonnekromatografi på aluminium-oksyd (30 g) og eluert med toluén. Fraksjonene inneholdende den ønskede forbindelse ble konsentrert under redusert trykk, hvilket
ga en farveløs, viskøs olje av 2,6-bis(nitroksymetyl)pyridin (5,1 g).
IR-spektrum (nujol) : ^ may. s = 1635,1600, 1460, 1285, 1160, 970
og 850 cm ^.
NMR-spektrum (CDC13): 6 (ppm) =5,50(4H, s), 2,34 (2H, d, J=8Hz), 7.78 (1H, t, J=8Hz).
Analyse:
Beregnet for C^NgOg: C 36,69, H 3,08, N 18,34
Funnet: C 36,97, H 3,16, N 18,64.
Eksempel 3
De følgende forbindelser ble oppnådd på lignende måte
som forbindelsene i eksempel 1 og 2.
1) 2-(2-nitroksyetyl)pyridinnitrat, sm.p. 49-52°C.
IR-spektrum (nujol):<v>makg<=>2560, 2110, 1635, 1625, 1405, 1315 og 1280 cm ^.
NMR-spektrum (dimetylsulfoksyd-dg): 6 (ppm) = 3,51 (2H, t, J=6Hz), 4,99 (2H, t, J=6Hz), 7,8-8,3 (2H, m), 8,59 (1H, dt, J=8 og 2 Hz), 8,93 (1H, dd, J=6 og 2 Hz), 13,45 (1H, s) .
Analyse:
Beregnet for C^N^ ,HN03: C 36,37, H 3,92, N 18,18
Funnet: C 35,97, H 3,86, N 18,19.
2) 2-(1-nitroksymety1-2-nitroksyety1)pyridin-hydroklorid,
sm.p. 111-112°C.
IR-spektrum (nuj<ol>)<:><V>maks = 2420, 1620, 1460, 1275, 990, 870, 840 og 750 cm"<1.>
NMR-spektrum (dimetylsulfoksyd-dg): 6 (ppm) = 2,32 (1H, kvintett, J=6Hz), 5,14 (4H, d, J=6Hz), 7,90 (1H, m), 8,14 (1H, d, J=8Hz), 8,47 (1H, dt, J= 8 og 2 Hz), 8,87 (1H, dd, J = 4 og 2 Hz),
18,20 (1H, bred s).
Analyse:
Beregnet for CgHgN-jOg ,HC1: C 34,36, H 3,60, N 15,03, Cl 12,68 Funnet: C 34,13, H 3,61, N 14,78, Cl 12,50. 3) 2,6-bis(nitroksymetyl)-4-klorpyridin, sm.p. 30-35°C.
IR-spektrum (nujol): vmaks = 1638,1582, 1278, 1043, 847 og
756 cm ^.
NMR-spektrum (CDC13): 6 (ppm) = 5,52 (4H, s), 7,35 (2H, s) . Analyse:
Beregnet for C^HgClN-jOg: C 31,89, H 2,29, N 15,94
Funnet: C 32,06, H 2,29, N 16,12.
4) 4-(3-nitroksypropyl)pyridin.
IR-spektrum (nujol): vmakg = 1625, 1410, 1275, 865, 800 og 760 cm"1. NMR-spektrum (CC14): 6 (ppm) = 1,7-2,4 (2H, m), 2,73 (2H, t, J=7Hz) , 4,41 (2H, t, J=7Hz), 7,03 (2H, d, J=5Hz), 8,39 (2H, d, J=5Hz) .
Analyse: '
Beregnet for c8Hl0N2°3: C 52,74, H 5,53, N 15,38
Funnet: C 53,19, H 5,64, N 15,30 5) 2-nitroksymetyl-6-metylpyridin-hydroklorid, sm.p. 65-68°C.
IR-spektrum (nujol): ^ ma] liS = 1635, 1275, 1171, 999, 847 og
837 cm"<1.>
NMR-spektrum (CC14i fri form): 6 (ppm) = 2,48 (3H, s), 5,40
(2H, s), 7,02 (1H, d, J=8Hz), 7,04 (1H, d, J=8Hz), 7,49 (1H, t, J=8Hz).
Analyse:
Beregnet for C7HgN203,HC1: C 41,09, H 4,43, N 13,69
Funnet: C 40,80, H 4,42, N 13,68
6) 2-nitroksymetyl-6-klorpyridin.
IR-spektrum (nujol): vm = 1636, 1585, 1563, 1439, 1281, 1160, 1138, 985, 846 og 785 cm .
NMR-spektrum (CC14): 6 (ppm) = 5,47 (2H, s), 7,15-7,45 (2H, m), 7,69 (1H, dd, J=8,5 og 6Hz).
Analyse:
Beregnet for C6H5C1N203: C 38,22, H 2,67, N 14,86
Funnet: C 37,97, H 2,75, N 14,95.
Claims (10)
1. Fremgangsmåte for fremstilling av en pyridylalkylnitratforbindelse med den generelle formel
hvor R <1> er hydrogen, lavere alkyl, halogen eller nitroksy-lavere alkyl, en av R 2 og R 3 er mono- eller di-nitroksy-lavere 2 3
alkyl og den annen av R og R er hydrogen eller halogen, eller farmasøytisk godtagbare salter derav,
karakterisert ved at en forbindelse med den
generelle formel
hvor, R er hydrogen, lavere alkyl, halogen eller hydroksy-lavere alkyl, én av R <2> og R 3er mono- eller dihydroksy-lavere alkyl og den annen av R 2 og R 3er hydrogen eller halogen, eller salter EL cl derav eller dens reaktive derivat ved hydroksygruppen(e) på hydroksy-lavere alkyl-gruppen(e), omsettes med et nitreringsmiddel for å danne en forbindelse med den generelle formel
12 3
hvor R , R og R er som angitt ovenfor, eller salter derav.
2. Fremgangsmåte ifølge krav 1, karakterisert ved at det fremstilles en forbindelse hvor R <1> er hydrogen, metyl, klor eller nitroksymetyl, én av R 2 og R 3 er nitroksymetyl, 2-nitroksyetyl, 3-nitroksypropyl eller l-nitroksymetyl-2-nitroksy-2 3
etyl og den annen av R og R er hydrogen eller klor.
3. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2-nitroksymetylpyridin eller dets nitrat.
4. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2,6-bis(nitroksymetyl)pyridin.
5. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2-(2-nitroksyetyl)pyridin eller dets nitrat.
6. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2-(l-nitroksymetyl-2-nitroksyetyl)-pyridin eller dets hydroklorid.
7. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2,6-bis(nitroksymetyl)-4-klorpyriidn.
8. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 4-(3-nitroksypropyl)-pyridin.
9. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2-nitroksymetyl-6-metylpyridin eller dets hydroklorid.
10. Fremgangsmåte ifølge krav 2, karakterisert ved at det fremstilles 2-nitroksymetyl-6-klorpyridin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8221592 | 1982-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO832700L true NO832700L (no) | 1984-02-06 |
Family
ID=10531922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO832700A NO832700L (no) | 1982-07-26 | 1983-07-25 | Fremgangsmaate for fremstilling av en pyridylalkylnitratforbindelse. |
Country Status (17)
Country | Link |
---|---|
US (2) | US4540701A (no) |
EP (1) | EP0100081B1 (no) |
JP (1) | JPS5951263A (no) |
KR (1) | KR900005470B1 (no) |
AT (1) | ATE40948T1 (no) |
AU (1) | AU565791B2 (no) |
CA (1) | CA1216850A (no) |
DE (1) | DE3379255D1 (no) |
DK (1) | DK311683A (no) |
ES (1) | ES8502088A1 (no) |
FI (1) | FI832490L (no) |
GR (1) | GR78629B (no) |
HU (1) | HU190497B (no) |
NO (1) | NO832700L (no) |
PH (1) | PH18083A (no) |
SU (1) | SU1189337A3 (no) |
ZA (1) | ZA835048B (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6081166A (ja) * | 1983-10-11 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | 2−ニトロオキシメチル−6−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法 |
JPS6215A (ja) * | 1985-02-26 | 1987-01-06 | Fujisawa Pharmaceut Co Ltd | 2−ニトロオキシメチル−6−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤 |
ZA885069B (en) * | 1987-07-24 | 1989-03-29 | Fujisawa Pharmaceutical Co | Sustained-release percutaneous preparations |
JPH02167279A (ja) * | 1988-09-30 | 1990-06-27 | Taisho Pharmaceut Co Ltd | アポビンカミン酸誘導体 |
US5047543A (en) * | 1988-11-24 | 1991-09-10 | Taisho Pharmaceutical Co., Ltd. | 1,4-dihydropyridine derivatives |
CN106318877A (zh) * | 2016-08-29 | 2017-01-11 | 刘翔 | 一种从茯砖茶中分离、纯化冠突散囊菌及其液态培养方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3275642A (en) * | 1962-04-26 | 1966-09-27 | Bard Pharmaceutical Inc | 3-pyridine carbinol nitrate and its preparation |
US3689494A (en) * | 1971-03-31 | 1972-09-05 | William R J Simpson | N-pyridinealkyl-alkanolamine nitrates |
-
1983
- 1983-07-05 DK DK311683A patent/DK311683A/da not_active Application Discontinuation
- 1983-07-07 FI FI832490A patent/FI832490L/fi not_active Application Discontinuation
- 1983-07-07 AU AU16635/83A patent/AU565791B2/en not_active Ceased
- 1983-07-11 GR GR71903A patent/GR78629B/el unknown
- 1983-07-11 ZA ZA835048A patent/ZA835048B/xx unknown
- 1983-07-19 JP JP58132645A patent/JPS5951263A/ja active Granted
- 1983-07-20 PH PH29255A patent/PH18083A/en unknown
- 1983-07-20 US US06/515,653 patent/US4540701A/en not_active Expired - Fee Related
- 1983-07-22 ES ES524375A patent/ES8502088A1/es not_active Expired
- 1983-07-23 DE DE8383107232T patent/DE3379255D1/de not_active Expired
- 1983-07-23 EP EP83107232A patent/EP0100081B1/en not_active Expired
- 1983-07-23 AT AT83107232T patent/ATE40948T1/de not_active IP Right Cessation
- 1983-07-25 NO NO832700A patent/NO832700L/no unknown
- 1983-07-25 SU SU833625197A patent/SU1189337A3/ru active
- 1983-07-25 HU HU832615A patent/HU190497B/hu unknown
- 1983-07-26 CA CA000433162A patent/CA1216850A/en not_active Expired
- 1983-07-26 KR KR1019830003459A patent/KR900005470B1/ko active IP Right Grant
-
1985
- 1985-05-08 US US06/731,893 patent/US4613608A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI832490L (fi) | 1984-01-27 |
CA1216850A (en) | 1987-01-20 |
EP0100081A2 (en) | 1984-02-08 |
US4613608A (en) | 1986-09-23 |
DE3379255D1 (en) | 1989-04-06 |
AU565791B2 (en) | 1987-10-01 |
EP0100081B1 (en) | 1989-03-01 |
GR78629B (no) | 1984-09-27 |
JPS5951263A (ja) | 1984-03-24 |
US4540701A (en) | 1985-09-10 |
FI832490A0 (fi) | 1983-07-07 |
ES524375A0 (es) | 1984-12-16 |
SU1189337A3 (ru) | 1985-10-30 |
AU1663583A (en) | 1984-02-02 |
ZA835048B (en) | 1984-03-28 |
DK311683D0 (da) | 1983-07-05 |
DK311683A (da) | 1984-01-27 |
KR840005426A (ko) | 1984-11-12 |
JPS6350343B2 (no) | 1988-10-07 |
ATE40948T1 (de) | 1989-03-15 |
PH18083A (en) | 1985-03-18 |
KR900005470B1 (ko) | 1990-07-30 |
EP0100081A3 (en) | 1985-05-02 |
HU190497B (en) | 1986-09-29 |
ES8502088A1 (es) | 1984-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002335031B2 (en) | Himbacine analogues as thrombin receptor antagonists | |
NZ334389A (en) | Cyclic amine derivatives | |
AU2010323116A1 (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
JP2000509408A (ja) | 2−アミノ−6−(2−置換−4−フェノキシ)−置換ピリジン | |
JPH0395144A (ja) | アミノフェノール誘導体の製造方法 | |
EP2343296A1 (en) | A process for the purification of paliperidone | |
JP5066638B2 (ja) | ピリジン−1−オキシド誘導体及びその医薬的に有効な化合物へと転換する為の方法 | |
KR20000064387A (ko) | 1-벤질-4-((5,6-디메톡시-1-인다논)-2-일)메틸피페리딘을제조하기위한방법및중간체 | |
EP0161422B1 (en) | Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient | |
NO832700L (no) | Fremgangsmaate for fremstilling av en pyridylalkylnitratforbindelse. | |
JP2023545352A (ja) | 結晶性edg-2受容体アンタゴニストおよび製造方法 | |
JP3907029B2 (ja) | 環状アミン誘導体を含有する医薬 | |
JP3053418B2 (ja) | 新規の置換アルキルピペリジンとコレステロール合成阻害剤としてのその用途 | |
JP3274088B2 (ja) | 環状アミン誘導体 | |
NO325155B1 (no) | Nye desloratadinhemisulfat, fremgangsmate for deres syntese og farmasoytiske preparater derav | |
EP0228314A2 (en) | Use of ethanol/amine derivatives in treating or preventing hyperlipemia | |
JP2815150B2 (ja) | 置換されたジベンゾシクロヘプテンイミン | |
JPS61161278A (ja) | 3‐置換インドールの調製方法 | |
AU594686B2 (en) | Process for the preparation of 2-halonicergoline derivatives and their acid addition salts and new 2-halonicergolines | |
SK1582000A3 (en) | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ì (54) -ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE S | |
EP2206700A1 (en) | Crystalline form of flupirtine ((2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl)-carbamic acid ethyl ester) | |
JPS5910358B2 (ja) | 新規エルゴリン誘導体 | |
TAKAYANAGI et al. | Studies on the Chlorinated oz-Santonins. IV.“ | |
FR2601013A1 (fr) | Nouvelles quinazolinones tetracycliques, leur preparation et leur utilisation comme medicaments | |
EP0298890A2 (en) | New 2-(P-isobutylphenyl)-propionic acid ester and process for the preparation thereof |